st2825 and Subarachnoid-Hemorrhage

st2825 has been researched along with Subarachnoid-Hemorrhage* in 2 studies

Other Studies

2 other study(ies) available for st2825 and Subarachnoid-Hemorrhage

ArticleYear
Peroxiredoxin 2 activates microglia by interacting with Toll-like receptor 4 after subarachnoid hemorrhage.
    Journal of neuroinflammation, 2018, Mar-19, Volume: 15, Issue:1

    Peroxiredoxin (Prx) protein family have been reported as important damage-associated molecular patterns (DAMPs) in ischemic stroke. Since peroxiredoxin 2 (Prx2) is the third most abundant protein in erythrocytes and the second most protein in the cerebrospinal fluid in traumatic brain injury and subarachnoid hemorrhage (SAH) patients, we assessed the role of extracellular Prx2 in the context of SAH.. We introduced a co-culture system of primary neurons and microglia. Prx2 was added to culture medium with oxyhemoglobin (OxyHb) to mimic SAH in vitro. Neuronal cell viability was assessed by lactate dehydrogenase (LDH) assay, and neuronal apoptosis was determined by TUNEL staining. Inflammatory factors in culture medium were measured by ELISA, and their mRNA levels in microglia were determined by qPCR. Toll-like receptor 4 knockout (TLR4-KO) mice were used to provide TLR4-KO microglia; ST-2825 was used to inhibit MyD88, and pyrrolidine dithiocarbamate (PDTC) was used to inhibit NF-κB. Related cellular signals were analyzed by Western blot. Furthermore, we detected the level of Prx2 in aneurysmal SAH patients' cerebrospinal fluids (CSF) and compared its relationship with Hunt-Hess grades.. Prx2 interacted with TLR4 on microglia after SAH and then activated microglia through TLR4/MyD88/NF-κB signaling pathway. Pro-inflammatory factors were expressed and released, eventually caused neuronal apoptosis. The levels of Prx2 in SAH patients positively correlated with Hunt-Hess grades.. Extracellular Prx2 in CSF after SAH is a DAMP which resulted in microglial activation via TLR4/MyD88/NF-κB pathway and then neuronal apoptosis. Prx2 in patients' CSF may be a potential indicator of brain injury and prognosis.

    Topics: Animals; Animals, Newborn; Antioxidants; Cerebral Cortex; Coculture Techniques; Cytokines; Gene Expression Regulation; Heterocyclic Compounds, 2-Ring; Humans; In Situ Nick-End Labeling; L-Lactate Dehydrogenase; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Neurons; Oxyhemoglobins; Peroxiredoxins; Pyrrolidines; RNA, Messenger; Spiro Compounds; Subarachnoid Hemorrhage; Thiocarbamates; Toll-Like Receptor 4

2018
Inhibition of myeloid differentiation primary response protein 88 provides neuroprotection in early brain injury following experimental subarachnoid hemorrhage.
    Scientific reports, 2017, Nov-17, Volume: 7, Issue:1

    Accumulating of evidence suggests that activation of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs) exacerbates early brain injury (EBI) following subarachnoid hemorrhage (SAH) by provoking pro-inflammatory and pro-apoptotic signaling. Myeloid differentiation primary response protein 88 (MyD88) is an endogenous adaptor protein in the toll-like receptors (TLRs) and interleukin (IL) -1β family signaling pathways and acts as a bottle neck in the NF-κB and MAPK pathways. Here, we used ST2825, a selective inhibitor of MyD88, to clarify whether inhibiting MyD88 could provide neuroprotection in EBI following SAH. Our results showed that the expression of MyD88 was markedly increased at 24 h post SAH. Intracerebroventricular injection of ST2825 significantly reduced the expression of MyD88 at 24 h post SAH. Involvement of MAPKs and NF-κB signaling pathways was revealed that ST2825 inhibited SAH-induced phosphorylation of TAK1, p38 and JNK, the nuclear translocation of NF-κB p65, and degradation of IκBα. Further, ST2825 administration diminished the SAH-induced inflammatory response and apoptosis. As a result, SAH-induced EBI was alleviated and neurological deficits caused by SAH were reversed. Our findings suggest that MyD88 inhibition confers marked neuroprotection against EBI following SAH. Therefore, MyD88 might be a promising new molecular target for the treatment of SAH.

    Topics: Animals; Apoptosis; Brain Injuries; Cell Nucleus; Down-Regulation; Heterocyclic Compounds, 2-Ring; Inflammation; Male; MAP Kinase Signaling System; Myeloid Differentiation Factor 88; Neurons; Neuroprotection; NF-KappaB Inhibitor alpha; Protein Transport; Proteolysis; Rats, Sprague-Dawley; Spiro Compounds; Subarachnoid Hemorrhage; Transcription Factor RelA

2017